Emmett, CJ and Macintyre, K and Kitsos, AR and McKercher, CM and Jose, MD and Bettiol, S, Independent effect of haemodialysis session frequency and duration on survival in non-indigenous Australians on haemodialysis, Nephrology Article Epub ahead of print. ISSN 1320-5358 (2019) [Refereed Article]
© 2019 Asian Pacific Society of Nephrology
Background: End-stage kidney disease (ESKD) patients have increased mortality compared to the general population. Haemodialysis (HD) of more frequent and of longer duration has been proposed to improve survival but it remains unclear if this is attributed to increased frequency,duration, or both. We aimed to examine the independent effects of session frequency and duration on mortality in incident HD patients.
Methods: A retrospective cohort study was performed using data from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) examining non-Indigenous patients aged e 18years who initiated HD of e 3 sessions/week in Australia from 2001-2015. Initial dialysis prescription was categorised as session duration >5 hours/session compared to d5hours/session and session frequency as >3 sessions/week compared to 3 sessions/week. Survival analysis was performed using Cox regression analysis, with multivariable analysis controlling for available covariates.
Results: We examined 16,944 patients of whom 757 (4.5%) received >3 sessions/week and 518 (3.1%) received >5 hours/session. After controlling for frequency, patients initiated on HD sessions >5 hours had a significantly reduced risk of mortality compared with patients with HD session d5 hours (adjusted HR= 0.57; 95% CI 0.44-0.74). In contrast, patients initiated on >3 sessions/week of HD had a similar risk of death when compared with patients on 3 sessions/week of HD (adjusted HR= 0.97; 95% CI 0.84-1.13), after controlling for duration. Limitations include potential residual confounding and changes in exposure over time.
Conclusion: Longer duration rather than increased frequency of treatment appears to reduce mortality in HD patients. This has implications for management and requires further study.
|Item Type:||Refereed Article|
|Keywords:||Australian and New Zealand Data Registry (ANZDATA), end-stage kidney disease (ESKD), haemodialysis (HD), dialysis prescription, renal replacement therapy (RRT)|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Nephrology and urology|
|Objective Group:||Public health (excl. specific population health)|
|Objective Field:||Preventive medicine|
|UTAS Author:||Emmett, CJ (Dr Christopher Emmett)|
|UTAS Author:||Macintyre, K (Dr Kate Macintyre)|
|UTAS Author:||Kitsos, AR (Mr Alex Kitsos)|
|UTAS Author:||McKercher, CM (Dr Charlotte McKercher)|
|UTAS Author:||Jose, MD (Professor Matthew Jose)|
|UTAS Author:||Bettiol, S (Dr Silvana Bettiol)|
Repository Staff Only: item control page